Zhengjun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhengjun Li has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Huiling Su
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
2 shared publicationsJing Jia
Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
2 shared publicationsRiran Zhu
Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
2 shared publications- Yunqian Li
Department of Dermatology, Qilu Hospital of Shandong University, Jinan, Shandong, China
2 shared publications Yuxiang Mao
Medical School, Kunming University of Science and Technology, Kunming, China
2 shared publicationsFuqiang Chen
Department of Dermatology, Qilu Hospital, Shandong University, Jinan, China
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in Cell Death & Disease
PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common and aggressive skin cancer, with treatment options for advanced stages often limited by chemoresistance. Here, we observe a positive correlation between PHF20 expression and the malignancy and tumor grade of cSCC. Functional studies suggest that PHF20 promotes oncogenic phenotypes, including proliferation, invasion, and epithelial-mesenchymal transition. Notably, PHF20 depletion appears to sensitize cSCC cells to chemotherapeutic agents. Mechanistically, we show that PHF20 interacts with and promotes the ubiquitin-mediated degradation of GAS7. This downregulation of GAS7 is associated with nuclear F-actin assembly, a process that has been implicated in DNA damage repair (DDR). Consequently, PHF20 loss stabilizes GAS7, enhances nuclear F-actin assembly, and is accompanied by increased DNA damage accumulation. These in vitro findings were corroborated in vivo, where PHF20 knockdown suppressed tumor growth and increased DNA damage. Together, PHF20 may contribute to the regulation of DDR and chemotherapeutic response, highlighting its potential as a therapeutic target in poorly differentiated cSCC.
- 29 May 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessPHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (cSCC) is a common and aggressive skin cancer, with treatment options for advanced stages often limited by chemoresistance. Here, we observe a positive correlation between PHF20 expression and the malignancy and tumor grade of cSCC. Functional studies suggest that PHF20 promotes oncogenic phenotypes, including proliferation, invasion, and epithelial-mesenchymal transition. Notably, PHF20 depletion appears to sensitize cSCC cells to chemotherapeutic agents. Mechanistically, we show that PHF20 interacts with and promotes the ubiquitin-mediated degradation of GAS7. This downregulation of GAS7 is associated with nuclear F-actin assembly, a process that has been implicated in DNA damage repair (DDR). Consequently, PHF20 loss stabilizes GAS7, enhances nuclear F-actin assembly, and is accompanied by increased DNA damage accumulation. These in vitro findings were corroborated in vivo, where PHF20 knockdown suppressed tumor growth and increased DNA damage. Together, PHF20 may contribute to the regulation of DDR and chemotherapeutic response, highlighting its potential as a therapeutic target in poorly differentiated cSCC.
- Open Access
- 1 May 2025
- Published by Elsevier in Materials Today Bio
- Vol. 32
Enhancing the antioxidant capacity of Fe single-atom nanozymes through local coordination manipulation for psoriasis treatment
- 1 May 2025
- Published by Elsevier in Materials Today Bio
- Vol. 32
Open AccessEnhancing the antioxidant capacity of Fe single-atom nanozymes through local coordination manipulation for psoriasis treatment
- Open Access
- 1 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
The clinical application of conventional doxorubicin (CDOX) was constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal doxorubicin and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to Doxil/Caelyx, Myocet and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil/Caelyx, and Myocet were 42.45 (41.44; 43.48), 17.53 (16.02; 19.20), and 34.68 (26.63; 45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96 (14.10; 22.86), and 37.36 (19.34; 72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16 (5.69; 6.68), 36.13 (32.60; 40.06), and 19.69 (11.59; 33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that clinical monitoring for symptoms of cardiotoxicity of CDOX and Myocet, and PPE and interstitial lung disease of Doxil should be performed. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with Doxil and Myocet merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX were recommended.
- 1 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Open AccessA real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins
The clinical application of conventional doxorubicin (CDOX) was constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal doxorubicin and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to Doxil/Caelyx, Myocet and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil/Caelyx, and Myocet were 42.45 (41.44; 43.48), 17.53 (16.02; 19.20), and 34.68 (26.63; 45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96 (14.10; 22.86), and 37.36 (19.34; 72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16 (5.69; 6.68), 36.13 (32.60; 40.06), and 19.69 (11.59; 33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that clinical monitoring for symptoms of cardiotoxicity of CDOX and Myocet, and PPE and interstitial lung disease of Doxil should be performed. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with Doxil and Myocet merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX were recommended.
- Open Access
- 16 August 2023
- Published by Springer Nature in Research Square
Adverse events profiles of liposomal and conventional doxorubicins: An updated comprehensive analysis of the FDA adverse event reporting system
The clinical application of doxorubicin (DOX) is constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal DOX and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to liposomal doxorubicin and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil®/Caelyx®, and Myocet® were 42.45(41.44;43.48), 17.53(16.02;19.20), and 34.68(26.63;45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96(14.10;22.86), and 37.36(19.34;72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16(5.69;6.68), 36.13(32.60;40.06), and 19.69(11.59;33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that the use of CDOX warrants careful monitoring for cardiotoxicity, PPE, and interstitial lung disease, especially with Doxil®. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with liposomal doxorubicin merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX are recommended.
- 16 August 2023
- Published by Springer Nature in Research Square
Open AccessAdverse events profiles of liposomal and conventional doxorubicins: An updated comprehensive analysis of the FDA adverse event reporting system
The clinical application of doxorubicin (DOX) is constrained by its side effects. Liposomal doxorubicin was developed to mitigate these limitations, showing improved toxicity profiles. However, the adverse events associated with liposomal doxorubicin and CDOX have not yet been comprehensively evaluated in clinical settings. The FAERS data from January 2004 to December 2022 were collected to analyze the adverse events of liposomal DOX and CDOX. Disproportionate analysis and Bayesian analysis were employed to quantify this association. Our analysis incorporated 68,803 adverse event reports related to liposomal doxorubicin and CDOX. The relative odds ratios (RORs, 95%CI) for febrile neutropenia associated with CDOX, Doxil®/Caelyx®, and Myocet® were 42.45(41.44;43.48), 17.53(16.02;19.20), and 34.68(26.63;45.15) respectively. For cardiotoxicity, they were 38.87(36.41;41.49), 17.96(14.10;22.86), and 37.36(19.34;72.17). For Palmar-Plantar Erythrodysesthesia (PPE), the RORs were 6.16(5.69;6.68), 36.13(32.60;40.06), and 19.69(11.59;33.44). Regarding onset time, significant differences adverse events including neutropenia, PPE, pneumonia and malignant neoplasm progression. This study indicates that the use of CDOX warrants careful monitoring for cardiotoxicity, PPE, and interstitial lung disease, especially with Doxil®. Additionally, the onset time of febrile neutropenia, malignant neoplasm progression, and pneumonia associated with liposomal doxorubicin merits particular attention. Continuous surveillance, risk evaluations, and additional comparative studies between liposomal doxorubicin and CDOX are recommended.
- 21 March 2023
- Published by Springer Nature in Inflammation
- Vol. 46 (4) , 1209-1220
Long Non-Coding RNA-GDA-1 Promotes Keratinocyte Proliferation and Psoriasis Inflammation by Regulating the STAT3/NF-κB Signaling Pathway via Forkhead Box M1
Psoriasis is a chronic inflammatory skin disease associated with multiple comorbidities and complex pathogenesis. Long non-coding RNAs (lncRNAs) play an important regulatory role in many diseases, including psoriasis. In this study, We aimed to investigate the role and mechanism of lncRNA GDA-1 (GDA) in M5-treated psoriatic keratinocytes. GDA expression was significantly upregulated in psoriatic tissues and M5-treated keratinocytes. By silencing and overexpressing GDA in NHEKs and Ker-CT cells, we showed that GDA regulated proliferation and cell cycle and increased secretion of interleukin‐1β (IL‐1β), IL-6, and chemokine ligands 2 and 20 (CCL2 and CCL20). RNA sequencing after GDA silencing led to the identification of a close regulatory relationship between GDA and Forkhead Box M1 (FOXM1). GDA significantly influenced FOXM1 expression at both mRNA and protein levels and activated STAT3/NF-κB signaling pathways. STAT3 and NF-κB inhibition abrogated GDA effects on keratinocyte proliferation and inflammation. In conclusion, our study is the first to report that Lnc-GDA-1 distinctly regulates FOXM1 expression and mediates proliferation and inflammation of psoriatic keratinocytes through the STAT3/NF-κB signaling pathway, which may be a potent target for psoriasis treatment.
- 21 March 2023
- Published by Springer Nature in Inflammation
- Vol. 46 (4) , 1209-1220
Long Non-Coding RNA-GDA-1 Promotes Keratinocyte Proliferation and Psoriasis Inflammation by Regulating the STAT3/NF-κB Signaling Pathway via Forkhead Box M1
Psoriasis is a chronic inflammatory skin disease associated with multiple comorbidities and complex pathogenesis. Long non-coding RNAs (lncRNAs) play an important regulatory role in many diseases, including psoriasis. In this study, We aimed to investigate the role and mechanism of lncRNA GDA-1 (GDA) in M5-treated psoriatic keratinocytes. GDA expression was significantly upregulated in psoriatic tissues and M5-treated keratinocytes. By silencing and overexpressing GDA in NHEKs and Ker-CT cells, we showed that GDA regulated proliferation and cell cycle and increased secretion of interleukin‐1β (IL‐1β), IL-6, and chemokine ligands 2 and 20 (CCL2 and CCL20). RNA sequencing after GDA silencing led to the identification of a close regulatory relationship between GDA and Forkhead Box M1 (FOXM1). GDA significantly influenced FOXM1 expression at both mRNA and protein levels and activated STAT3/NF-κB signaling pathways. STAT3 and NF-κB inhibition abrogated GDA effects on keratinocyte proliferation and inflammation. In conclusion, our study is the first to report that Lnc-GDA-1 distinctly regulates FOXM1 expression and mediates proliferation and inflammation of psoriatic keratinocytes through the STAT3/NF-κB signaling pathway, which may be a potent target for psoriasis treatment.